Academic and Community Cancer Research United

A cancer research network conducting clinical trials that translate the latest

discoveries into new therapies for cancer treatment and symptom management

Our mission

ACCRU is a collaborative clinical research network of academic and community-based cancer centers with a goal to prevent cancer, cure cancer, and attenuate cancer-related symptoms.

 

Our members

Academic and Community Cancer Research United (ACCRU) is a cancer research network that includes clinicians and researchers from more than 110 leading academic medical centers and community oncology practices in the United States and internationally. Our members

 

ACCRU Website User Guide

 

Clinical trials

ACCRU has developed industry relationships that strengthen their position in the market.  Currently ACCRU has relationship in place with international research networks such as, International Cholangio-carcinoma Research Network (ICRN) and the Austria/Asian GI Trial Group (AGITG). There is a continually growing demand for the ability to conduct multi-site clinical trials with these groups. 

 

ACCRU has developed many relationships with industry funding sponsors as well.  These groups include but are not limited to, Bristol Myers Squibb, Celgene, Genentech, Seattle Genetics, Exact Science, Incyte, Five Prime, Janssen and Bayer

 

Services

The ACCRU Research Coordinating Center is based at the Mayo Clinic Cancer Center. We offer industry sponsors and collaborators a full range of clinical trial development and management services. Services

 

Making a difference

To date, ACCRU has achieved its mission to develop high quality clinical trials by:

 

  • Building a network of more than 110 academic medical center and community practices, offering over 490 treatment locations. 
  • Working with over 20 industry partners to develop clinical trials to advance cancer care.
  • Collaborating with national and international research networks to develop large scale, multicenter, cancer clinical trials.
  • Opening more than 65 phase II and III studies across many types of cancer.
  • Enrolling more than 3,000 patients in clinical trials testing the latest therapies. Clinical trials